Eli Lilly wins FDA approval for weight loss pill, tees up Novo rivalry
The US Food and Drug Administration (FDA) has approved Eli Lilly’s orforglipron pill for weight loss, ending Novo Nordisk’s first…
02 Apr 2026
Merck KGaA acquires JSR chromatography business
Germany-based Merck KGaA (Merck) has completed its previously announced acquisition of the chromatography business of JSR Life Sciences. This follows the company’s signing of a definitive agreement in October 2025…
02 Apr 2026
Biocytogen and Sihuan partner to advance new therapeutics for weight loss
Biocytogen has entered a strategic partnership with Sihuan Pharmaceutical to advance new therapeutics across several disease areas, including weight loss. Under the agreement, Biocytogen’s fully human antibody discovery platform will…
01 Apr 2026
Biogen uplifts rare disease pipeline with $5.6bn Apellis buyout
Biogen has forged a $5.6bn deal to acquire immunology and rare disease specialist Apellis Pharmaceuticals – marking another M&A milestone in a flurry of pharma deal activity at the end…
01 Apr 2026
Eli Lilly outlays $7.8bn to acquire sleep drug biotech Centessa
Eli Lilly will acquire neuroscience specialist Centessa Pharmaceuticals in a deal worth up to $7.8bn, solidifying the drugmaker’s status as one of the most dominant players in the pharma deals…
01 Apr 2026
Telomir seeks FDA approval for Telomir-1 to treat breast cancer
Telomir Pharmaceuticals has submitted an investigational new drug application to the US Food and Drug Administration for Telomir-1 (Telomir-Zn), its lead candidate targeting advanced and metastatic triple-negative breast cancer (TNBC).…
01 Apr 2026
Symeres and Ambagon collaborate for colorectal cancer molecules
Symeres has entered a collaboration with Ambagon Therapeutics on molecular glue research in colorectal cancer, aiming to address diseases considered difficult to treat. The partnership aims to explore a new…